Sanguine Web Site
sanguine-corp.com
PHER-O2 may also have applications in the home. PHER-O2 may be used in cleansers/deodorizers for
cleaning around the bath and kitchen, or around pets. It might find application in stain removers, clothing
treatments or detergent solutions, where oxygen is the key to reactivity.
PHER-O2 may also be an ideal treatment for oxygen-deficiency conditions, such as sickle cell crises,
carbon monoxide poisoning, hemolytic anemia, and bone marrow failure or suppression
PHER-O2 may also be used to treat fungal and bacterial infections of the skin and gastrointestinal infections.
When cells, bacteria and fungi are exposed to high concentrations of PHER-O2 the cells die due to oxygen
tension. PHER-O2 may have application in the treatment of tumors, wherein the tumors are injected with
oxygen rich PHER-O2 to cause the tumor cells to die.
Sanguine’s technology is applicable to uses where oxygenation is a need or concern. One of the greatest
potentials for the technology is in the treatment of Alzheimer’s Disease (AD). Data indicates that AD may be
a disease resulting from oxygen deficiency due to the poor microcirculation and presence of amyloid plaques
in the brain. An article by Dr. William Regelson published in the Annals of the New York Academy of
Sciences in 1997 specifically hypothesizes the potential of PFCs to oxygenate plaque-encased regions of
the brain to alleviate the symptoms of AD.
Imaging
NMR, CT Scan, x-ray technology requires an infusion of a traceable fluid for imaging. Alliance currently
markets a product called Imagent, which is a PFC-based compound that can be infused into the patient for
imaging purposes. PHER-O2 exhibits properties similar to Imagent, and may be a candidate for imaging
use, as well.
With over 300,000 open-heart procedures per year,
there is a demand of up to 1,200,000 pints of
precious blood for priming alone. PHER-O2 can be
available for immediate use, without the need of
blood typing, and without the further aggravation of
allergic reaction associated with human blood, or
toxicity associated with other blood substitutes.
Cardioplegia
Each open-heart procedure requires the use of a machine which recycles and cleans the patient’s own
blood. As the procedure takes place, high quantities of blood are expelled from the incision areas, which
contact other internal anatomy, and are exposed to air and other potential contaminants or activators. When
blood leaves its vascular confinement, it changes, becoming unfit for perfusion. Thus, the blood must be
recycled with the heart-lung machine, and returned to the body, where the blood can properly serve its
circulatory functions. The heart-lung machine must be primed with up to four pints of blood before it can be
used to process the patient’s blood.
In the 1960s, scientists discovered non-toxic and inert carriers of oxygen and carbon dioxide called
perfluorocarbons (PFC) that can be used in place of blood for temporary therapeutic effects. In 1990 the
FDA granted approval to the first and only human blood substitute product, Fluosol, developed by Japan’s
Green Cross Company after twenty years of research and clinical trials in animals and ten years in humans
in Japan, United States, and Europe. Green Cross-licensed Fluosol to their U.S. subsidiary Alpha
Therapeutics Corporation, which supplied Fluosol for successful use in over 13,000 patients per year for
three years. Half of Fluosol’s uses were off license for the application of transfusions legally prescribed by
doctors and the balance for its FDA approved angioplasty application.
In March 1990, Dr. Thomas Drees, who directed the development of Fluosol for Alpha Therapeutics, formed
a California corporation, which he named Sanguine, after the Latin word sanguis, which means blood. In
1993 Sanguine became publicly held as a result of being acquired by International Health Resorts, Inc., a
Nevada corporation. The Company is now a publicly held Nevada corporation, poised to market a second generation blood substitute product with broader applications than Fluosol.
PHER-O2 is superior to human blood, and hemoglobin-based blood substitutes for transfusions
for the following reasons:
• It can be sterilized.
• It does not come with the diseases that commonly plague human blood.
• It absorbs up to three to four times more oxygen than human blood per unit volume.
• It is universally accepted by all blood types.
• It can be manufactured in large volumes, eliminating the need for blood donors.
• It is stored at room temperature for extended periods of time.
• Its shelf life will far outlast the six-week characteristic of human blood.
• Its minimum compositional structure will provide it with the ability to oxygenate areas of the
body virtually inaccessible to the red blood cell.
With FDA approval, PHER-O2 could meet literally hundreds of medical applications including blood
transfusion, cardioplegia (in open heart surgery), heart attack, imaging, stroke, ophthalmic surgery, the
treatment of Alzheimer’s Disease, cancer, parasitic infections sensitive to high oxygen tension, and many
others. PHER-O2 may also have direct application in many non-medical fields where oxygenation is key,
such as combustion, waste treatment, protein synthesis via fermentation, and in cosmetics and toiletries.
How great is the demand for RED BLOOD CELLS?
There are over 6 billion humans with 20 pints of blood each.
60 million pints of donor blood yearly does not meet one-third of the world demand.
Donor blood is difficult to obtain and often infected with disease.
Donor blood must be typed and cross-matched
Donor blood must be discarded after 42 days. . . . . . . . . . .
. . . . . . . . . .SANGUINE has a better option. |
